The company has a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. Idorsia's development compounds target a number of different diseases such as resistant hypertension, systemic lupus erythematosus, chronic insomnia and Fabry disease, among others.

Idorsia's lead product, Quviviq (daridorexant), received US approval for 25mg and 50mg doses for the treatment of adults with insomnia in early 2022.

The drug is also approved in Switzerland, having received marketing authorization in December 2022; under review in Canada; and successfully completed Phase III trials in Japan with a filing expected in H1 2023.